BridgeBio Oncology Therapeutics Inc. (BBOT) Earnings History
Annual and quarterly earnings data from 2021 to 2025
Loading earnings history...
BBOT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BBOT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export BBOT earnings history in CSV or JSON format
Free sign-in required to download data
BridgeBio Oncology Therapeutics Inc. (BBOT) Earnings Overview
As of May 8, 2026, BridgeBio Oncology Therapeutics Inc. (BBOT) reported trailing twelve-month net income of -$134M, reflecting -1034.8% year-over-year growth. The company earned $-4.30 per diluted share over the past four quarters.
Looking at the long-term picture, BBOT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3,520 in fiscal 2022.
BridgeBio Oncology Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including BBIO (-$726M net income, -145.3% margin), KYMR (-$315M net income, -794.4% margin), TPVG (-$12M net income, 50.6% margin), BBOT has comparable earnings metrics. Compare BBOT vs BBIO →
BBOT Earnings vs Peers
Earnings metrics vs comparable public companies
BBOT Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$134M | -80.5% | -$146M | $-4.30 | - | - |
| 2024 | -$74M | -14.8% | -$81M | $0.46 | - | - |
| 2023 | -$65M | -1837939.8% | -$65M | $-0.00 | - | - |
| 2022 | $-3,520 | +91.9% | $-3,520 | $-0.00 | - | - |
| 2021 | $-43,357 | - | $-43,357 | $-0.00 | - | - |
See BBOT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BBOT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BBOT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBBOT — Frequently Asked Questions
Quick answers to the most common questions about buying BBOT stock.
Is BBOT growing earnings?
BBOT EPS fell to $-4.30, with earnings declining -1034.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-134M.
What are BBOT's profit margins?
BridgeBio Oncology Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are BBOT's earnings?
BBOT earnings data spans 2021-2025. The declining earnings trend is -1034.8% YoY. Historical data enables comparison across business cycles.